Noelia Nebot, is a Quantitative Clinical Pharmacologist and technology enthusiast with over 15 years of experience in drug development and life cycle management for both small and large molecules in oncology. She held global roles at GSK and Novartis where she worked with multidisciplinary teams to support overall project strategy and leading pharmacokinetic, bioanalytical and pharmacometric sub teams. She was responsible for leading the global clinical pharmacology strategy and supported dose selection in regulatory submissions leading to the worldwide approvals of targeted agents Tafinlar and Mekinist for multiple indications, treating over 100,000 patients and reaching blockbuster status in 2019. 

Noelia’s expertise encompasses designing, implementing and analysing clinical pharmacology studies, quantitative analysis (population PK/PD), authoring regulatory submission documents, and engaging with health authorities across the US, Europe, Canada and Japan. She currently consults for biotech and medtech companies through her firm, Conexias Advisory, and as part of the Syntegrity Quantitative Clinical Pharmacology Collaborative. She has also contributed to scale-up and academic initiatives, leveraging her ability to communicate complex science, work with different stakeholders and translate innovations into impactful solutions, from driving progress in methods to advance mRNA medicine development to genomics technologies.

A passionate educator, Noelia holds a lecturing position at the University of Sydney’s School of Pharmacy, where she has delivered courses on designing and conducting exploratory clinical studies and the application of modeling and simulation in drug development. She has co-authored numerous peer-reviewed publications and has been an invited speaker for courses on therapeutic drug development. Dedicated to fostering innovation, she actively mentors research scientists and start-up ecosystem members to promote gender parity and diversity.

Noelia earned her Ph.D. in Pharmaceutical Sciences from the University of Sydney and completed a PK/PD post-doctoral fellowship with GSK at the University of North Carolina. Her commitment to patient-focused care drives her collaborations with physicians, researchers, and industry partners to deliver precision medicine and transformative technologies to patients worldwide.